NASDAQ:SBPH - Spring Bank Pharmaceuticals Stock Price, Forecast & News

Spring Bank Pharmaceuticals trades on the NASDAQ under the ticker symbol "SBPH."

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) released its earnings results on Thursday, November, 7th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.19. View Spring Bank Pharmaceuticals' Earnings History.

Spring Bank Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Spring Bank Pharmaceuticals.

5 brokers have issued 1-year price objectives for Spring Bank Pharmaceuticals' stock. Their forecasts range from $1.70 to $29.00. On average, they anticipate Spring Bank Pharmaceuticals' share price to reach $14.43 in the next twelve months. This suggests a possible upside of 607.1% from the stock's current price. View Analyst Price Targets for Spring Bank Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spring Bank Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spring Bank Pharmaceuticals.

News stories about SBPH stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Spring Bank Pharmaceuticals earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Spring Bank Pharmaceuticals.

Spring Bank Pharmaceuticals saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 24,300 shares, a decrease of 9.0% from the December 15th total of 26,700 shares. Based on an average daily trading volume, of 242,600 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the company's stock are sold short. View Spring Bank Pharmaceuticals' Current Options Chain.

Some companies that are related to Spring Bank Pharmaceuticals include CV Sciences (CVSI), OASMIA PHARMACE/ADR (OASM), NeuBase Therapeutics (NBSE), Oncolytics Biotech (ONCY), Aduro BioTech (ADRO), Otonomy (OTIC), Scpharmaceuticals (SCPH), Bellicum Pharmaceuticals (BLCM), Millendo Therapeutics (MLND), Stealth BioTherapeutics (MITO), Axovant Gene Therapies (AXGT), Aquestive Therapeutics (AQST), Synlogic (SYBX), Sesen Bio (SESN) and AVEO Pharmaceuticals (AVEO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spring Bank Pharmaceuticals investors own include Intelsat (I), Fossil Group (FOSL), AMC Entertainment (AMC), Bank of America (BAC), Associated British Foods (ABF), Chaarat Gold (CGH), Apollo Global Management (APO), China Unicom (Hong Kong) (CHU), Ciena (CIEN) and First Data (FDC).

(SBPH) raised $14 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 1,100,000 shares at a price of $12.00-$14.00 per share. Dawson James Securities served as the underwriter for the IPO.

Shares of SBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBPH stock can currently be purchased for approximately $2.04.

Spring Bank Pharmaceuticals has a market capitalization of $33.62 million. The company earns $-22,850,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Spring Bank Pharmaceuticals employs 29 workers across the globe.View Additional Information About Spring Bank Pharmaceuticals.

The official website for Spring Bank Pharmaceuticals is http://springbankpharm.com/.

Spring Bank Pharmaceuticals' mailing address is 35 PARKWOOD DRIVE SUITE 210, HOPKINTON MA, 01748. The company can be reached via phone at 508-473-5993 or via email at [email protected]